Regenxbio Q1 2024 GAAP EPS $(1.38) Misses $(1.23) Estimate, Sales $15.622M Miss $23.525M Estimate
Portfolio Pulse from Benzinga Newsdesk
Regenxbio (NASDAQ:RGNX) reported Q1 2024 earnings with a GAAP EPS of $(1.38), missing the $(1.23) estimate, and sales of $15.622M, missing the $23.525M estimate. This represents a 9.8% increase in losses per share and an 18.37% decrease in sales from the same period last year.
May 08, 2024 | 9:37 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Regenxbio reported a larger than expected Q1 2024 loss and a significant miss in sales, indicating potential challenges in its operational performance.
The significant miss in both earnings per share and sales compared to analyst estimates suggests operational challenges and could lead to negative investor sentiment in the short term. The year-over-year increase in losses and decrease in sales further emphasize the company's current struggles, likely impacting the stock negatively.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100